Comparison of MRI-based and PET-based image pre-processing for quantification of 11C-PBB3 uptake in human brain

Yousefzadeh-Nowshahr, Elham; Winter, Gordon; Bohn, Peter; Kneer, Katharina; Arnim, Christine A. F. Von; Otto, Markus; Solbach, Christoph; Anderl‐Straub, Sarah; Polívka, D; Fissler, Patrick; Prasad, Vikas; Kletting, Peter; Riepe, Matthias W.; Higuchi, Makoto; Ludolph, Albert C.; Beer, Ambros J.; Glatting, Gerhard

doi:10.1016/j.zemedi.2020.12.002

Cited by 2 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main strength of this study is to provide semi-automated techniques to analyse the PET data. The PET-based quantitative method was used to quantify tau-PET scans [ 26 ]. For amyloid-PET quantification, the adaptive template method was utilized due to the different activity distribution patterns in amyloid-positive and -negative patients [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

“…Various studies have shown that the spatial normalization using PET templates are highly effective for quantification of hypometabolism and amyloid deposition using PET [ 23 – 25 ]. The feasibility of a PET-based method for the quantification of 11 C-PBB3 tracer was also evaluated in our previous study [ 26 ].…”

Section: Methodsmentioning

confidence: 99%

“…Subsequently, all 23 individual 11 C-PBB3-PET images were spatially normalized into the 11 C-PBB3 template using the ‘old normalization’ module of SPM12 [ 28 ]. A detailed description of the method can be found in [ 26 ].…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting

et al. 2022

Self Cite

View full text Add to dashboard Cite

Purpose The recent developments of tau-positron emission tomography (tau-PET) enable in vivo assessment of neuropathological tau aggregates. Among the tau-specific tracers, the application of 11C-pyridinyl-butadienyl-benzothiazole 3 (11C-PBB3) in PET shows high sensitivity to Alzheimer disease (AD)-related tau deposition. The current study investigates the regional tau load in patients within the AD continuum, biomarker-negative individuals (BN) and patients with suspected non-AD pathophysiology (SNAP) using 11C-PBB3-PET. Materials and methods A total of 23 memory clinic outpatients with recent decline of episodic memory were examined using 11C-PBB3-PET. Pittsburg compound B (11C-PIB) PET was available for 17, 18F-flurodeoxyglucose (18F-FDG) PET for 16, and cerebrospinal fluid (CSF) protein levels for 11 patients. CSF biomarkers were considered abnormal based on Aβ42 (< 600 ng/L) and t-tau (> 450 ng/L). The PET biomarkers were classified as positive or negative using statistical parametric mapping (SPM) analysis and visual assessment. Using the amyloid/tau/neurodegeneration (A/T/N) scheme, patients were grouped as within the AD continuum, SNAP, and BN based on amyloid and neurodegeneration status. The 11C-PBB3 load detected by PET was compared among the groups using both atlas-based and voxel-wise analyses. Results Seven patients were identified as within the AD continuum, 10 SNAP and 6 BN. In voxel-wise analysis, significantly higher 11C-PBB3 binding was observed in the AD continuum group compared to the BN patients in the cingulate gyrus, tempo-parieto-occipital junction and frontal lobe. Compared to the SNAP group, patients within the AD continuum had a considerably increased 11C-PBB3 uptake in the posterior cingulate cortex. There was no significant difference between SNAP and BN groups. The atlas-based analysis supported the outcome of the voxel-wise quantification analysis. Conclusion Our results suggest that 11C-PBB3-PET can effectively analyze regional tau load and has the potential to differentiate patients in the AD continuum group from the BN and SNAP group.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer’s Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers

Strobel,

Yousefzadeh-Nowshahr,

Deininger

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Accurately diagnosing Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD) is challenging due to overlapping symptoms and limitations of current imaging methods. This study investigates the use of [11C]PBB3 PET/CT imaging to visualize tau pathology and improve diagnostic accuracy. Given diagnostic challenges with symptoms and conventional imaging, [11C]PBB3 PET/CT’s potential to enhance accuracy was investigated by correlating tau pathology with cerebrospinal fluid (CSF) biomarkers, positron emission tomography (PET), computed tomography (CT), amyloid-beta, and Mini-Mental State Examination (MMSE). We conducted [11C]PBB3 PET/CT imaging on 24 patients with suspected AD or FTLD, alongside [11C]PiB PET/CT (13 patients) and [18F]FDG PET/CT (15 patients). Visual and quantitative assessments of [11C]PBB3 uptake using standardized uptake value ratios (SUV-Rs) and correlation analyses with clinical assessments were performed. The scans revealed distinct tau accumulation patterns; 13 patients had no or faint uptake (PBB3-negative) and 11 had moderate to pronounced uptake (PBB3-positive). Significant inverse correlations were found between [11C]PBB3 SUV-Rs and MMSE scores, but not with CSF-tau or CSF-amyloid-beta levels. Here, we show that [11C]PBB3 PET/CT imaging can reveal distinct tau accumulation patterns and correlate these with cognitive impairment in neurodegenerative diseases. Our study demonstrates the potential of [11C]PBB3-PET imaging for visualizing tau pathology and assessing disease severity, offering a promising tool for enhancing diagnostic accuracy in AD and FTLD. Further research is essential to validate these findings and refine the use of tau-specific PET imaging in clinical practice, ultimately improving patient care and treatment outcomes.

show abstract

Comparison of MRI-based and PET-based image pre-processing for quantification of 11C-PBB3 uptake in human brain

Cited by 2 publications

References 37 publications

Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting

Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting

Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer’s Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers

Contact Info

Product

Resources

About